Experienced in Ectopic Cushing's syndrome

Zhenmei Y. An

Chengdu, CN 
Experienced in Ectopic Cushing's syndrome
Chengdu, CN 
OverviewLocationsClinical Research

Overview

Zhenmei An practices in Chengdu, China. An is rated as an Experienced expert by MediFind in the treatment of Ectopic Cushing's syndrome. Their top areas of expertise are Gout, Adrenal Gland Adenoma, Cushing's syndrome, and Muscle Atrophy.

Their clinical research consists of co-authoring 77 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Ectopic Cushing's syndrome.

Locations

Chengdu, China
Other Locations
China
Yantai, 264005, China
Chongqing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Tirzepatide
A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Tirzepatide
Enrollment Status: Completed
Publish Date: July 06, 2023
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 1
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Drugs: Dulaglutide, Insulin Glargine
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Study Phase: Phase 3
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: March 29, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

77 Total Publications

Osteoblast ferroptosis driven by iron overload: Implications for osteoporosis pathogenesis and FTH1/GPX4-targeted therapy.
Osteoblast ferroptosis driven by iron overload: Implications for osteoporosis pathogenesis and FTH1/GPX4-targeted therapy.
Journal: Biochemical and biophysical research communications
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find An's expertise for a condition
ConditionClose
        View All 26 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile